

CURRICULUM VITAE

Huilin Tang, M.Sc.

Email: tang.huilin@ufl.edu

Address: 1225 Center Drive, Gainesville, FL, 32610

Google scholar: <https://scholar.google.com/citations?user=JQumGwIAAAAJ&hl=en>

EDUCATION

- **PhD Student** in Pharmaceutical Outcomes and Policy (August 2021 to present)
University of Florida, Gainesville, Florida
- **M.Sc.** in Clinical Pharmacy (Sep 2008 to July 2011)
Peking University, Beijing, China.
- **B.Sc.** in Pharmaceutical Sciences (Sep 2004 to July 2008)
Xiamen University, Xiamen, China.

WORK EXPERIENCE

University of Florida College of Pharmacy, Department of Pharmaceutical Outcomes and Policy, Gainesville, FL

Graduate Assistant (August 2021 to present)

EvidPro, LLC, Fishers, IN.

Manager (Mar 2020 to July 2021)

- Responsible for communication with clients.
- Conducted systematic review and meta-analysis projects.
- Performed data-analysis as requested.

Peking University Health Science Center, Institute for Drug Evaluation, Beijing, China.

Adjunct Researcher (Aug 2017 to July 2021)

- Conducted research to evaluate the effectiveness and safety of drugs using systematic review and meta-analysis.
- Conducted data-analysis to evaluate the safety of drug using pharmacovigilance databases (Beijing Pharmacovigilance database or U.S. FDA Adverse Event Reporting System).

Indiana University Richard M. Fairbanks School of Public Health, Department of Epidemiology, Indianapolis, IN.

Visiting scholar (Sep 2015 to Aug 2017)/**Research Associate** (Sep 2017 to Aug 2019)

- Conducted data analysis of population cohorts (NHS and HPFS cohorts) and electronic medical records data (Vanderbilt University Medical Center).
- Responsible for study design, conducting systematic review and meta-analysis of relevant research.
- Responsible for the publication of research papers, submitting conference abstracts, and presenting at research conferences.

Peking University Third Hospital, Department of Pharmacy, Beijing, China.

Clinical Pharmacist (Aug 2011 to Sep 2017; visiting scholar at IU from Sep 2015 to Aug 2017)

- Conducted research to evaluate the effectiveness and safety of drugs using systematic review and meta-analysis.
- Provided evidence and assessed evidence using GRADE for clinical guideline development.
- Performed rapid review and health technology assessment for customers or decision makers.
- Responsible for counseling from patients, physicians, and nurses.
- Performed chart reviews and provided physicians with timely information and advice on adverse drug events, drug interactions, appropriate dosages, duration of use, and routes of administration.

RESEARCH EXPERIENCE

Pharmacoepidemiology

- Assessed the safety of specific drugs using electronic medical records data (Vanderbilt University Medical Center) and pharmacovigilance database (Beijing Pharmacovigilance database or U.S. FDA Adverse Event Reporting System).

Evidence Synthesis and Health Technology Assessment

- Performed systematic review and meta-analysis (involving dose-response analysis and network meta-analysis) to evaluate the effectiveness, safety or economy of the drugs and to evaluate the role of pharmacogenetics in drug use.
- Assessed the overall evidence of off label drugs and developed clinical guideline based on the GRADE framework.
- Performed health technology assessment to evaluate the value of the drug for market access and reimbursement in China.
- Performed cost-effectiveness analysis of drugs.

Precision Medicine

- Conducted prospective cohort to evaluate the association between genetic biomarkers (e.g, FSHR polymorphism) and outcomes of In Vitro Fertilization.
- Performed prospective cohort to evaluate the effectiveness and safety of genotype-guided dosing algorithms in patients with indications for oral anticoagulation with warfarin.

CLINICAL EXPERIENCE

- Performed genetic test and gave the advice for warfarin/clopidogrel dosage according to patient's genetic information.
- Responsible for the consultations from patients, physicians and nurses and provide physicians with timely information and advice on adverse reaction, drug interactions, and appropriate dosages.

SELECTED PUBLICATIONS

2021

1. Zhao M, Sun S, Huang Z, Wang T, Tang H* (corresponding author). Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury. *Clin J Am Soc Nephrol*.2021;16(1):70-78.
2. Tang H* (corresponding author), Mourad SM, Wang A, Zhai SD, Hart RJ. Dopamine agonists for preventing ovarian hyperstimulation syndrome. *Cochrane Database Syst Rev*. 2021;4CD008605.
3. Hartman RI, Tang H (Co-first), Hang D, Song M, Nan H, Li X. Red Hair Color is Associated with Elevated C-Reactive Protein Levels among U.S. Women. *Journal of Investigative Dermatology*. 2021,141 (5), 1342-1344.
4. Tang H* (corresponding author), Zhou L, Li X, Kinlaw AC, Yang JY, Moon AM, Barnes EL, Wang T. Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data. *Int J Clin Pharm*. 2021;43(4):1116-22.
5. Xin L, Sun S, Wang J, Lu W, Wang T, Tang H* (corresponding author). Dipeptidyl Peptidase 4 Inhibitors and Venous Thromboembolism Risk in Patients with Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials. *Thromb Haemost*, 2021, 121 (01), 106-108
6. Fan Z, Guo G, Che X, Yang Y, Liu Y, Li L, Chang X, Han L, Cai X, Tang H* (corresponding author). Efficacy and safety of Lianhuaqingwen for mild or moderate coronavirus disease 2019: A meta-analysis of randomized controlled trials. *Medicine (Baltimore)*. 2021;100(21):e26059.

2020

7. Lu W, Sun S, Wei J, Thai, S, Li D, Tang H, Wang T, Sun L. Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system. *Int J Clin Pharm*,2020,42:1364-1368.
8. Li H, Hu Y, Tang H, Li S, Ding H, Zhai S, Zhao R. The Potential of Glycyrrhizinate in the Management of COVID-19: A Systematic Review of the Efficacy and Safety of Glycyrrhizin Preparations in the Treatment of SARS and MERS. *Am J Chin Med*. 2020;48(7):1539-1552.
9. Li D, Wu T, Wang T, Wei H, Wang A, Tang H* (corresponding author), Song Y* (corresponding author). Effects of sodium glucose co-transporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *Pharmacoepidemiology and Drug Safety*, 29(5):582-590.
10. Tang H, Yang K, Li X, Song Y, Han J. Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. *Pharmacoepidemiol Drug Saf*, 2020 Feb;29(2):161-172.
11. Guo W, Tang H (Co-first), Wang D, Zhou X, Song Y, Wang Z. Effect of short-term vitamin D supplementation after nonsurgical periodontal treatment: A randomized, double-masked, placebo-controlled clinical trial. *J Periodontal Res*, 2020, 55(3):354-362.

2019

12. Wang T, Yang JY, Buse JB, Pate V, Tang H, Barnes EL, Sandler RS, Stürmer T. Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-World Evidence in U.S. Adults. *Diabetes care* 42 (11), 2065-2074.
13. Li G, Crowley MJ, Tang H, Yang JY, Sandler RS, Wang T. Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. *Diabetes Care*. 2019 Jul;42(7):e119-e121.
14. Wang A, Yang K, Wang T, Zhang N, Tang H* (corresponding author), Feng X. Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and meta-analysis. *Diabetes Metab Res Rev*. 2019 May 3:e3174.
15. Yi ZM, Chen SD, Tang QY, Tang HL, Zhai SD. Efficacy and safety of sertraline for the treatment of premature ejaculation: Systematic review and meta-analysis. *Medicine (Baltimore)*. 2019 Jun;98(23):e15989.
16. Wang T, Lu W, Tang H, Buse JB, Stürmer T, Gower EW. Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System. *Diabetes Care*. 2019 42 (6), e89-e91.
17. Tang H, Shi W, Song Y, Han J. Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients: A systematic review and meta-analysis. *J Am Acad Dermatol*. 2019;80(2):500-507.e10.

2018

18. Tang H, Li D, Li Y, Zhang X, Song Y, Li X. Effects of Vitamin D Supplementation on Glucose and Insulin Homeostasis and Incident Diabetes among Nondiabetic Adults: A Meta-Analysis of Randomized Controlled Trials. *International Journal of Endocrinology*. 2018, Article ID 7908764, 9 pages.
19. Tang H, Yang K, Song Y, Han J. Meta-analysis of the association between sodium-glucose cotransporter 2 inhibitors and risk of skin cancer among patients with type 2 diabetes. *Diabetes Obes Metab*. 2018 20 (12), 2919-2924.
20. Li X, Thai S, Lu W, Sun S, Tang H, Zhai S, Wang T. Traditional Chinese medicine and drug-induced anaphylaxis: data from the Beijing pharmacovigilance database. *International journal of clinical pharmacy*. 2018, 40 (4), 921-927.
21. Men P, Li XT, Tang HL, Zhai SD. Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis. *PLoS One* 2018;13: e0197321.
22. Tang H, Li G, Zhao Y, Wang F, Gower EW, Shi L, Wang T. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis. *Diabetes Obes Metab* 2018; 20:1262-1279.
23. Tang H, Shi W, Fu S, Wang T, Zhai S, Song Y, Han J. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. *Cancer Med* 2018; 7:1070-1080.
24. Li D, Shi W, Wang T, Tang H*(corresponding author). SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis. *Diabetes Obes Metab*. 2018 Aug;20(8):1972-1976.

25. Zhao Y, Lu H, Thai S, Li X, Hui J, Tang H, Zhai S, Sun L, Wang T. Development and validation of an algorithm to identify drug-induced anaphylaxis in the Beijing Pharmacovigilance Database. *Int J Clin Pharm*. 2018; 40(4):862-869.
26. Li D, Yang JY, Wang T, Shen S, Tang H. Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials. *Diabetes Metab*. 2018 Nov;44(5):410-414.
27. Tang H, Fu S, Zhai S, Song Y, Asgari MM, Han J. Use of antihypertensive drugs and risk of keratinocyte carcinoma: A meta-analysis of observational studies. *Pharmacoepidemiol Drug Saf*. 2018 Mar;27(3):279-288.
28. Xing Y, Zhang H, Sun S, Ma X, Pleasants R, Tang H, Zheng H, Zhai S, Wang T. Clinical features and treatment of pediatric patients with drug-induced anaphylaxis: a study based on pharmacovigilance data. *Eur J Pediatr*, 2018 Jan;177(1):145-154.
29. Zhao Y, Sun S, Li X, Ma X, Tang H, Sun L, Zhai S, Wang T. Drug-induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database. *Int J Clin Pharm*. 2018; 40(5):1349-1358.

2017

30. Yang K, Marley A, Tang H, Song Y, Tang JY, Han J. Statin use and non-melanoma skin cancer risk: a meta-analysis of randomized controlled trials and observational studies. *Oncotarget*. 2017 Aug 8;8(43):75411-75417.
31. Tang H, Fu S, Zhai S, Song Y, Han J. Use of Antihypertensive Drugs and Risk of Malignant Melanoma: A Meta-analysis of Observational Studies. *Drug Saf*. 2018;41(2):161-169.
32. Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. *Diabetologia*. 2017, 60 (10), 1862-1872.
33. Tang H, Wu W, Fu S, Zhai S, Song Y, Han J. Phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis. *J Am Acad Dermatol*. 2017, 77 (3), 480-488.e9.
34. Tang H, Li D, Zhang J, Li Y, Wang T, Zhai S, Song Y. Sodium–glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. *Diabetes Obes Metab*. 2017, 19 (8), 1106-1115.
35. Wang T, Ma X, Xing Y, Sun S, Zhang H, Stürmer T, Wang B, Li X, Tang H, Jiao L, Zhai S. Use of Epinephrine in Patients with Drug-Induced Anaphylaxis: An Analysis of the Beijing Pharmacovigilance Database. *Int Arch Allergy Immunol* 2017, 173(1):51-60.
36. Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H*(corresponding author). Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. *Diabetes Obes Metab*. 2017, 19(3):348-355.
37. Tang H, Cui W, Li D, Wang T, Zhang J, Zhai S, Song Y. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. *Diabetes Obes Metab*. 2017, 19(1):142-147.

2016

38. Tang H*(corresponding author), Mourad S, Zhai SD, Hart RJ. Dopamine agonists for preventing ovarian hyperstimulation syndrome. *Cochrane Database Syst Rev.* 2016, 11:CD008605.
39. Tang H, Li D, Wang T, Zhai S, Song Y. Effect of sodium–glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. *Diabetes Care* 2016, 39(8):e123-4 [research letter].
40. Tang H, Li D, Zhang J, Hsu Y, Wang T, Zhai S, Song Y. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. *Diabetes Obes Metab.* 2016, 18(12):1199-1206.
41. Tang H, Fang Z, Wang T, Cui W, Zhai S, Song Y. Meta-Analysis of Effects of SGLT2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality among Patients with Type 2 Diabetes Patients. *Am J Cardiol.* 2016, 118(11):1774-1780.
42. Tang H, Zhang X, Zhang J, Li Y, Del Gobbo L, Zhai S, Song Y. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. *Diabetologia.* 2016, 59(12):2546-2551.
43. Li X, Yu C, Wang T, Chen K, Zhai S, Tang H*(corresponding author). Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: A systematic review and meta-analysis. *Eur J Clin Pharmacol.* 2016 72(10):1185-93.
44. Wang T, Wang F, Zhou J, Tang H, Giovenale S. Adverse Effects of Incretin-based Therapies on Major Cardiovascular and Arrhythmia Events: Meta-analysis of Randomized Trials. *Diabetes Metab Res Rev.* 2016, 32(8):843-857.
45. Jin H, Wang T, Falcione BA, Olsen KM, Chen K, Tang H, Hui J, Zhai S. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. *J Antimicrob Chemother.* 2016, 71(7):1772-85.
46. Pleasants RA, Wang T, Gao J, Tang H, Donohue JF. Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis. *Drugs.* 2016, 76(3):343-361.

2015

47. Tang HL, Shi WL, Li XG, Zhang T, Zhai SD, Xie HG. Limited clinical utility of genotype-guided warfarin initiation dosing algorithms versus standard therapy: a meta-analysis and trial sequential analysis of 11 randomized controlled trials. *Pharmacogenomics J.* 2015, 15(6): 496–504.
48. Li D, Wang T, Shen S, Cheng S, Yu J, Zhang Y, Zhang C, Tang H* (corresponding author). Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis. *PLoS One.* 2015; 10: e0145066.
49. Tang H, Yan Y, Wang T, Zhang T, Shi W, Fan R, et al. Effect of follicle-stimulating hormone receptor Asn680Ser polymorphism on the outcomes of controlled ovarian hyperstimulation: an updated meta-analysis of 16 cohort studies. *J Assist Reprod Genet.* 2015, 32(12): 1801-1810.

50. Ren ZY, Xu XQ, Bao YP, He J, Shi L, Deng JH, Gao XJ, Tang HL, Wang YM, Lu L. The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis. *Pain Physician*. 2015, 18(2):131-52.
51. Wang T, Benedict N, Olsen KM, Luan R, Zhu X, Zhou N, Tang H, Yan Y, Peng Y, Shi L. Effect of critical care pharmacist's intervention on medication errors: A systematic review and meta-analysis of observational studies. *J Crit Care*. 2015, 30(5):1101-6.
52. Shi WL, Tang HL, Zhai SD. Effects of CYP3A4*1B genetic polymorphism on pharmacokinetics of tacrolimus in adult renal transplant recipients: A meta-analysis. *PLOS ONE*. 2015, 10(6):e0127995.
53. Wang T, Wang F, Gou Z, Tang H, Li C, Shi L, Zhai S. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1 324 515 patients from observational studies. *Diabetes Obes Metab*. 2015, 17(1):32-41.

Before 2015

54. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of *H. pylori* infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. *PLoS One* 2013, 8(4):e62162.
55. Ye ZK, Tang HL, Zhai SD. Benefits of Therapeutic Drug Monitoring of Vancomycin: A Systematic Review and Meta-Analysis. *PLoS ONE*, 2013, 8(10): e77169.
56. Tang H*(corresponding author), Hunter T, Hu Y, Zhai SD, Sheng X, Hart RJ. Cabergoline for preventing ovarian hyperstimulation syndrome. *Cochrane Database of Systematic Reviews* 2012, Issue 2. Art. No.: CD008605.pub2.
57. Li Y, Tang HL, Hu YF, Xie HG. The Gain-of-Function Variant Allele CYP2C19*17: A Double-Edged Sword Between Thrombosis and Bleeding in Clopidogrel-Treated Patients. *J Thromb Haemost*. 2012, 10(2):199-206.
58. Tang HL, Xie HG, Yao Y, Hu YF. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 non-expressers than expressers *Pharmacogenet Genomics*, 2011, 21(11):713-20.
59. Yao Y, Ma CH, Tang HL, Hu YF. Influence of follicle-stimulating hormone receptor (FSHR) Ser680Asn polymorphism on ovarian function and in-vitro fertilization outcome: A meta-analysis. *Mol Genet Metab*. 2011, 103(4):388-93.
60. Tang HL, Ma LL, Xie HG, Zhang T, Hu YF. Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis. *Pharmacogenet Genomics*. 2010, 20(9): 525-531.

SELECTED PRESENTATIONS

1. Tang H, Xia J, Yang K, Yiqing Song. Comparative Effectiveness of Long-term Lifestyle Modification and Pharmacological Interventions for Primary Prevention of Type 2 Diabetes Mellitus: A Network Meta-analysis of Randomized Controlled Trials. American Heart Association EPI | Lifestyle 2019 Scientific Sessions. Houston, Texas; March 5-8, 2019 (Oral presentation).

2. Tang H, Shi W, Fu S, Wang T, Zhai S, Song Y, Han J. Pioglitazone and Risk of Bladder Cancer: A Cumulative Meta-analysis. American Diabetes Association's 77th Scientific Sessions, San Diego, California. Jun 9-13, 2017 (Moderated Poster presentation).
3. Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J. Sodium - Glucose Cotransporter 2 Inhibitors and Risk of Cancer in Pa. American Diabetes Association's 77th Scientific Sessions, San Diego, California. Jun 9-13, 2017 (Poster presentation).
4. Tang H, Fang Z, Wang T, Cui W, Zhai S, Song Y. Effects of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular Outcomes and Mortality: A Comprehensive Network Meta-Analysis. ISPE’s 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), Dublin, Ireland. August 25-28, 2016 (Oral presentation).
5. Tang H, Fang Z, Wang T, Cui W, Zhai S, Song Y. Effects of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular Outcomes and Mortality: A Comprehensive Network Meta-Analysis. American Diabetes Association's 76th Scientific Sessions, New Orleans, Louisiana. Jun 10-14, 2016 (Moderated Poster).
6. Tang HL, Shi WL, Li XG, Zhang T, Zhai SD, Xie HG. Pharmacogenetics Algorithms for Individualizing Warfarin Dosing: Meta-Analysis of Randomized Controlled Trials. 8th Asian Conference on pharmacoepidemiology. HongKong, 25-27th Oct 2013. (Oral presentation).
7. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effect of CYP2C19 variants on the Proton Pump Inhibitor (PPI)-Based Triple Therapy for Helicobacter pylori (H. pylori) Eradication: Meta-Analysis of randomized clinical trials (RCTs). FIP Centennial Congress of Pharmacy and Pharmaceutical Sciences, Amsterdam, Netherlands, October 3-8, 2012 (Oral presentation).

PROFESSIONAL ACTIVITIES

Peer reviewer for New England Journal of Medicine, BMJ, Diabetes, Obesity and Metabolism, Scientific Reports, PLOS ONE, British Journal of Clinical Pharmacology, Diabetes Research and Clinical Practice, Journal of Assisted Reproduction and Genetics, The Journal of Obstetrics and Gynecology Research, Chinese Journal of Evidence-Based Medicine, etc.

PROFESSIONAL HONORS AND AWARDS

1. Travel Award, 8th Asian Conference on Pharmacoepidemiology (Hongkong), 2013.
2. Andrew McAfee Award (coauthor), International Society for Pharmacoepidemiology, 2018.
3. Peking University Innovation Award, 2009-2010.
4. Peking University Guanghua Scholarship, 2009-2010.

RESEARCH GRANTS AND FUNDS

1. Application of mini-Health technology assessment (HTA) in selection of new drugs in hospital, funded by Peking University Third Hospital
Role: Principal Investigator *Jan 2015 – Dec 2015*
2. Evidence-based assessment system of off-label drug use, funded by Beijing Pharmaceutical Association

Role: Principal Investigator

Oct 2014 – Jul 2015

3. Health technology assessment (HTA) of lanthanum carbonate, funded by Fresenius Kabi

Role: Principal Investigator

Jan 2014 – Dec 2014

4. Health technology assessment (HTA) of Saxagliptin, funded AstraZeneca

Role: Principal Investigator

Jan 2015 – Dec 2015